Académique Documents
Professionnel Documents
Culture Documents
Dyslipidemia Pathophysiology
Dyslipidemia refers to a lipid profile that increases risk for
atheroscerotic development.
High (LDL) Low density lipoprotein
Low (HDL) High density lipoprotein
Who is at risk?
Individuals who:
Family History
Genetic
Obesity
Age & Sex
65 yrs. & males
Smoke
Physical Inactivity
Impaired Fasting Glucose
Near/Above
Optimal
Borderli
ne High
High
Very High
LDL
<100 mg/dL
100-129 mg/dL
130-159
mg/dL
160-189
mg/dL
Total
Cholesterol
<200 mg/dL
<200 mg/dL
200-239
mg/dL
240 mg/dL
Triglyceride
<150 mg/dL
150-199
mg/dL
200-499
mg/dL
HDL
500 mg/dL
High
Low
60 mg/dL
Treatments
Therapeutic Lifestyle Changes (TLC)
Drug therapy
Surgical approaches
Treatments
Goals depend on risk factors and risk score
Framingham Point Scores
Risk Factors
Physical inactivity
High blood pressure
Overweight/Obesity
Diabetes
Treatment:
Therapeutic Lifestyle Changes
Patients w/ dyslipidemia start w/ TLC
National Cholesterol Education Program
Managed by National Heart, Lung, and Blood
Institute (NHLBI)
TLC Diet
Weight management
Physical activity
LDL Reduction
Saturated fat
810%
Dietary cholesterol
Decrease to less
than 200 mg/day
35%
Soluble fiber
35%
Plant sterols/stanols
Add 2 grams/day
515%
Weight
Lose 10 pounds
if overweight
58%
Total
2030%*
Drug Therapy
Considered when
lipid results are high
lipid levels remained high after 6 months of TLC
Drugs Administered
Surgical Approaches
Surgical Approaches
Liver Transplant
Complications
blood clots
donated liver failure
infection
rejection of new liver
Side Effects
diarrhea
headaches
bone thinning
high blood pressure
DRUG THERAPY
Type/Class
LDL
HDL
TG
Contradictions
Adverse Effects
Statins
Decrease
dramatically
Increa
ses
Decrea
ses
Liver Disease
Myopathy
Increased transaminases
Decreases
Slightl
y
increa
ses
No
effect
or
slightly
increas
es
Elevated TG
GI distress
Decreased absorption of other drugs
Decreases
Increa
ses
Decrea
ses
Severe liver
disease
Severe gout
Flushing Hyperglycemia
Gout, Hepatotoxicity
Decreases
Increa
ses
Decrea
ses
Severe hepatic or
renal insufficiency
Cholesterol
absorption inhibitors
Decreases
No
chang
e
No
change
Statin
contraindications
Nicotinic Acid
Fibrates
Ezetimibe Zetia
Case Study
The patient is a 55 year old Hispanic male that is 69 tall, and weighs 215 lbs. with a BMI of 31.7. Three months ago he
weighed 195 lbs. His family history includes his father with HTN and his mother has diabetes mellitus. He does not
smoke and exercises twice a week. His breakfast consists of cereal with whole milk and a cup of coffee. He goes out to
dinner usually on the weekends and likes to order a good steak, hamburger, or occasionally fish. He orders out for lunch
with his company or takes out clients to lunch to restaurants. He cooks for himself at night. He usually makes pasta,
pizza, mexican dishes, or a sandwich. His lipid profile is as follows:
Total Cholesterol- 219 mg/dL
Triglycerides 330 mg/dL
HDL 44mg/dL
LDL 109 mg/dL
PES statements
1.
2.
3.
Excessive fat intake related to patient reporting high levels of saturated fat intake as evidenced by high Triglyceride
levels .
Excessive energy intake related to lack of daily caloric intake knowledge as evidenced by a BMI of 30.
Unintended weight gain related to eating out as evidenced by an increase of 20 pounds in 3 months.
Quiz
What is dyslipidemia usually characterized by?
a)
b)
c)
What diet focuses on reducing fat, increasing physical activity, and increasing fruits, vegetables, and fiber?
a)
Weight Watchers
b)
Atkins Diet
c)
b)
c)
References
Goldberg, A. (2013, October 1). Dyslipidemia. Retrieved February 11, 2015, from http://www.merckmanuals.
com/professional/endocrine_and_metabolic_disorders/lipid_disorders/dyslipidemia.html
Griffin, R. (2009, February 2). Plant Sterols and Stanols for Helping High Cholesterol. Retrieved February 10, 2015, from http:
//www.webmd.com/cholesterol-management/features/low-cholesterol-diet-plant-sterols-stanols
Heitz, D. (2014, January 6). Plasmapheresis. Retrieved February 10, 2015, from http://www.healthline.
com/health/plasmapheresis#Overview1
Kopin, L., & Goldmann, D. (2007). In the Clinic dyslipidemia. Annals of Internal, 9, 16-16. Retrieved January 24, 2105, from http:
//www.med.unc.edu/medselect/education/eduactivities/ITC Lipids article .full.pdf
References cont.
Lehrer, J. (2014, May 15). Liver transplant: MedlinePlus Medical Encyclopedia. Retrieved February 11, 2015, from http://www.
nlm.nih.gov/medlineplus/ency/article/003006.htm
Livertox-ANTILIPEMIC [LIPID-LOWERING] AGENTS. (2013, December 5). Retrieved February 1, 2015, from http://livertox.
nih.gov/Lipid-LoweringAgents.htm
National Cholesterol Education Program Slide Show. (2013, May 1). Retrieved February 11, 2015, from http://cvdrisk.nhlbi.nih.
gov/ncep_slds/menu.htm#4
Nelms, M., Sucher, K., (January 2015). Medical Nutrition Therapy: Cengage Learning. Pg. 308-311
Therapeutic Lifestyle Changes (TLC) Diet for High Cholesterol-Overview. (n.d.). Retrieved February 10, 2015, from http://www.
webmd.com/cholesterol-management/tc/therapeutic-lifestyle-changes-tlc-diet-for-high-cholesterol-